基因组编辑供者来源同种异体抗CD19 CAR-T细胞治疗儿童及成人B细胞急性淋巴细胞白血病:两项1期研究结果
两项多中心1期研究评估了基因组编辑供者来源同种异体抗CD19 CAR-T产品UCART19在复发或难治性B细胞急性淋巴细胞白血病儿童和成人中的可行性、安全性和抗白血病活性。21例患者接受UCART19,细胞因子释放综合征最常见(91%),14例(67%)在输注后28天达到完全缓解或完全缓解伴血液学不完全恢复。研究首次证明同种异体基因组编辑CAR-T细胞治疗侵袭性白血病的可行性,安全性可控。
要点
- UCART19在重预处理儿童和成人R/R B-ALL中显示体内扩增和抗白血病活性。
- 细胞因子释放综合征最常见(91%),3-4级占14%,安全性总体可控。
- 未接受阿仑单抗的4例患者无UCART19扩增或抗白血病活性。
核心结论
- 两项1期研究首次证明使用同种异体基因组编辑CAR-T细胞治疗侵袭性白血病可行。
- UCART19在重预处理儿童和成人R/R B-ALL中显示体内扩增和抗白血病活性,安全性可控。
研究设计与样本
- 两项正在进行中的多中心1期临床试验,评估UCART19的安全性和抗白血病活性。
- 纳入7例儿童和14例成人复发或难治性B细胞急性淋巴细胞白血病患者,均接受氟达拉滨和环磷酰胺预处理,联合或不联合阿仑单抗。
- 儿童接受UCART19剂量为1·1-2·3 × 10^6细胞/kg,成人接受6 × 10^6细胞、6-8 × 10^7细胞或1·8-2·4 × 10^8细胞的剂量递增。
- 主要结局指标为首次输注至数据截止期间的不良事件。
主要发现
- 细胞因子释放综合征为最常见不良事件,19例(91%)发生,其中3例(14%)为3-4级。
- 8例(38%)发生1或2级神经毒性,2例(10%)发生1级急性皮肤移植物抗宿主病,6例(32%)发生4级持续性血细胞减少。
- 发生2例治疗相关死亡:1例死于中性粒细胞减少性脓毒症(合并细胞因子释放综合征),1例死于肺出血(伴持续性血细胞减少)。
- 21例患者中14例(67%)在输注后28天达到完全缓解或完全缓解伴血液学不完全恢复。
- 未接受阿仑单抗的4例患者无UCART19扩增或抗白血病活性。
临床怎么用
- UCART19为同种异体基因组编辑CAR-T产品,可即时临床使用,拓宽了治疗可及性和适用性。
- 对于快速进展且自体CAR-T不可用的R/R B-ALL患者,UCART19提供了治疗机会。
- 治疗前需进行氟达拉滨和环磷酰胺预处理,联合阿仑单抗可能对UCART19扩增和抗白血病活性必要。
局限性
- 两项均为1期小样本研究,样本量有限。
- 研究正在进行中,数据截止时随访时间有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Genome-edited donor-derived allogeneic anti-CD19 chimeric antigen receptor (CAR) T cells offer a novel form of CAR-T-cell product that is available for immediate clinical use, thereby broadening access and applicability. UCART19 is one such product investigated in children and adults with relapsed or refractory B-cell acute lymphoblastic leukaemia. Two multicentre phase 1 studies aimed to investigate the feasibility, safety, and antileukaemic activity of UCART19 in children and adults with relapsed or refractory B-cell acute lymphoblastic leukaemia. METHODS: We enrolled paediatric or adult patients in two ongoing, multicentre, phase 1 clinical trials to evaluate the safety and antileukaemic activity of UCART19. All patients underwent lymphodepletion with fludarabine and cyclophosphamide with or without alemtuzumab, then children received UCART19 at 1·1-2·3 × 106 cells per kg and adults received UCART19 doses of 6 × 106 cells, 6-8 × 107 cells, or 1·8-2·4 × 108 cells in a dose-escalation study. The primary outcome measure was adverse events in the period between first infusion and data cutoff. These studies were registered at ClinicalTrials.gov, NCT02808442 and NCT02746952. FINDINGS: Between June 3, 2016, and Oct 23, 2018, seven children and 14 adults were enrolled in the two studies and received UCART19. Cytokine release syndrome was the most common adverse event and was observed in 19 patients (91%); three (14%) had grade 3-4 cytokine release syndrome. Other adverse events were grade 1 or 2 neurotoxicity in eight patients (38%), grade 1 acute skin graft-versus-host disease in two patients (10%), and grade 4 prolonged cytopenia in six patients (32%). Two treatment-related deaths occurred; one caused by neutropenic sepsis in a patient with concurrent cytokine release syndrome and one from pulmonary haemorrhage in a patient with persistent cytopenia. 14 (67%) of 21 patients had a complete response or complete response with incomplete haematological recovery 28 days after infusion. Patients not receiving alemtuzumab (n=4) showed no UCART19 expansion or antileukaemic activity. The median duration of response was 4·1 months with ten (71%) of 14 responders proceeding to a subsequent allogeneic stem-cell transplant. Progression-free survival at 6 months was 27%, and overall survival was 55%. INTERPRETATION: These two studies show, for the first time, the feasibility of using allogeneic, genome-edited CAR T cells to treat patients with aggressive leukaemia. UCART19 exhibited in-vivo expansion and antileukaemic activity with a manageable safety profile in heavily pretreated paediatric and adult patients with relapsed or refractory B-cell acute lymphoblastic leukaemia. The results this study are an encouraging step forward for the field of allogeneic CAR T cells, and UCART19 offers the opportunity to treat patients with rapidly progressive disease and where autologous CAR-T-cell therapy is unavailable. FUNDING: Servier.
引用
- Benjamin R, Graham C, Yallop D, et al. Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies. Lancet. 2020. PMID: 33308471. doi:10.1016/S0140-6736(20)32334-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。